We are live on ! Find out more
TLSI icon

TriSalus Life Sciences
TLSI

19 hedge funds and large institutions have $5.74M invested in TriSalus Life Sciences in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,000% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 1

721% more capital invested

Capital invested by funds: $699K → $5.74M (+$5.04M)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

111% more funds holding

Funds holding: 9 → 19 (+10)

2.05% more ownership

Funds ownership: 0.52% → 2.57% (+2.1%)

Holders
19
Holders Change
+10
Holders Change %
+111.11%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
3
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$850K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$559K
3
HA
HC Advisors
Georgia
+$524K
4
HF
HRT Financial
New York
+$247K
5
LNWWM
Laird Norton Wetherby Wealth Management
California
+$180K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$41.8K
2
WAM
Wolverine Asset Management
Illinois
-$2.12K

TLSI Hedge Fund Activity: Q4 2023 in Review

19 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q4 2023, worth a combined $5.74M — up 721% from $699K a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new TLSI positions and 1 closed out — a net gain of 10 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $850K. The largest seller was UBS Group, cutting an estimated $41.8K.

  • 19 institutional investors held TriSalus Life Sciences (TLSI) as of Q4 2023, up from 9 in Q3 2023.
  • Funds reported $5.74M of TriSalus Life Sciences stock for Q4 2023, up 721% quarter-over-quarter.
  • 11 funds opened new TriSalus Life Sciences positions in Q4 2023 and 1 closed out, a net change of +10 holders.
  • The largest TriSalus Life Sciences buyer in Q4 2023 was Vanguard Group, an estimated $850K added.
  • The largest TriSalus Life Sciences seller in Q4 2023 was UBS Group, an estimated $41.8K sold.

Based on aggregated 13F filings for Q4 2023.